Key facts
- SunRegen’s last known valuation is $24.1M (Dec 2024).
- It has raised $1.8M; the latest was Reverse Merger ($9.1M) in Aug 2024.
- Notable investors include European Union, APEX Ventures (Seehausen), BASELAUNCH, GoBeyond.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for SunRegen
- ·The full record, as it builds
Funding rounds
No funding rounds for SunRegen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SunRegen
Operator of a biopharmaceutical company intended to develop drugs to treat neurodegenerative diseases. The company's services mainly focus on innovative treatments for patients suffering from neurological, neuromuscular, and ophthalmic disorders, developing drug candidates with solid neuroprotective effects against multiple misfolded protein aggregates, neurite outgrowth-promoting effects, enabling clients to get access to an anticipated favorable safety and tolerability profile to bring life-changing treatments to patients.
- Sector
- Healthcare
- HQ
- Reinach, Switzerland
- Founded
- 2017
- Employees
- 3
- Website
- sunregen.ch/
- Ownership
- Privately Held (backing)
SunRegen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SunRegen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SunRegen in its N-PORT filings yet. We sweep new filings monthly.